TY - JOUR
T1 - Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline
T2 - A Longitudinal Study
AU - Wake, Taisei
AU - Tabuchi, Hajime
AU - Funaki, Kei
AU - Ito, Daisuke
AU - Yamagata, Bun
AU - Yoshizaki, Takahito
AU - Nakahara, Tadaki
AU - Jinzaki, Masahiro
AU - Yoshimasu, Haruo
AU - Tanahashi, Iori
AU - Shimazaki, Hiroumi
AU - Mimura, Masaru
N1 - Funding Information:
The authors thank all the participants and the staff at the Department of Radiology and the Department of Microbiology and Immunology at Keio University for their support in the administration of PET, MRI, and SPECT. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. This work was funded by PIRAMAL Imaging S.A., Matran, Switzerland; Meiji Yasuda Mental Health Foundation; and JSPS KAKENHI Grant Number JP16K10223.
Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. This work was funded by PIRAMAL Imaging S.A., Matran, Switzerland; Meiji Yasuda Mental Health Foundation; and JSPS KAKENHI Grant Number JP16K10223.
Publisher Copyright:
© The Author(s) 2020.
PY - 2020
Y1 - 2020
N2 - This study aimed to investigate the long-term impacts of disclosing amyloid status for a risk of Alzheimer disease (AD) to cognitively normal research participants with subjective cognitive decline (SCD), which represents an initial manifestation of AD. Forty-two participants were classified as the amyloid-positive (n = 10) or amyloid-negative (n = 32) groups. We assessed symptoms of anxiety, depression, and test-related distress at 6, 24, and 52 weeks after results disclosure. No difference was found over time in anxiety, depression, and test-related distress in either group. Although no significant differences were observed between groups in anxiety or depression, the amyloid-negative group had a significantly higher level of test-related distress than the amyloid-positive group at 52 weeks. Disclosing amyloid status to cognitively healthy research participants with SCD did not cause significant long-term psychological risks. However, a theoretical spectrum of subjective concern may exist about cognitive decline in amyloid-negative individuals.
AB - This study aimed to investigate the long-term impacts of disclosing amyloid status for a risk of Alzheimer disease (AD) to cognitively normal research participants with subjective cognitive decline (SCD), which represents an initial manifestation of AD. Forty-two participants were classified as the amyloid-positive (n = 10) or amyloid-negative (n = 32) groups. We assessed symptoms of anxiety, depression, and test-related distress at 6, 24, and 52 weeks after results disclosure. No difference was found over time in anxiety, depression, and test-related distress in either group. Although no significant differences were observed between groups in anxiety or depression, the amyloid-negative group had a significantly higher level of test-related distress than the amyloid-positive group at 52 weeks. Disclosing amyloid status to cognitively healthy research participants with SCD did not cause significant long-term psychological risks. However, a theoretical spectrum of subjective concern may exist about cognitive decline in amyloid-negative individuals.
KW - Alzheimer disease
KW - amyloid imaging
KW - disclosure
KW - ethics
KW - subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85079335166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079335166&partnerID=8YFLogxK
U2 - 10.1177/1533317520904551
DO - 10.1177/1533317520904551
M3 - Article
C2 - 32052640
AN - SCOPUS:85079335166
SN - 1533-3175
VL - 35
JO - American journal of Alzheimer's disease and other dementias
JF - American journal of Alzheimer's disease and other dementias
ER -
